Alnylam Drops Label-Expansion Effort For Onpattro After FDA Complete Response

 
• By Joseph Haas
Change of plan
Alnylam has revised its plans in cardiomyopathy following an FDA rejection • Source: Shutterstock

More from Strategy

More from Business